Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LLY vs AVDL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Captures Overall Composite Edge (62.9 BUY vs 41.4 SELL), While LLY Leads 5–1 on Growth & Valuation Pillars

AVDL Overall Winner 6-Pillar Tally: LLY 5 – 1 AVDL Matrix Metrics: LLY 5 – 5 AVDL

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Eli Lilly & Co. (LLY) on higher Unified Composite conviction (62.9/100 BUY vs. 41.4/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while LLY wins 5–1 across the 6-pillar growth and valuation breakdown. LLY trades at $1,347.11 (26.5x Forward P/E, 51.2% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. LLY 41.4/100 SELL) and 0.14β · 2% Vol risk profile, whereas LLY leads top-line expansion (+38.6% YoY revenue growth, 1.28x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LLY vs AVDL
LLY NYSE
Eli Lilly & Co.
Pharmaceutical Preparations
$1,347.11
-0.3% 1D
Market Cap $1.20T
TTM Revenue $86.5B
Forward P/E 26.5x
Beta / 30D Vol 0.32β · 36% Vol
Unified Composite Score
41.4 / 100 SELL
Tech 39.0 Fund 44.0 Flow 67.0 Mom 21.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.5 · SMA20: $1,383.91 · SMA50: $1,266.92
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50

6-Pillar Scorecard Institutional Category Breakdown (LLY 5 – 1 AVDL)

Columns: Metric · LLY · AVDL
1. Valuation Multiples AVDL
Forward P/E 26.5x 28.8x
Trailing P/E 44.9x 16.8x
PEG Ratio 1.28x 0.07x
EV / Revenue 14.4x 8.5x
2. Growth & Scale LLY
Revenue Growth (YoY) +38.6% +54.9%
Earnings Growth (YoY) +16.3% +0.0%
TTM Revenue (USD) $86.5B $249M
Market Cap $1.20T $2.1B
3. Profitability & Quality LLY
Gross Margin 83.6% 94.9%
Operating Margin 51.2% 2.5%
Net Profit Margin 31.9% -0.1%
Return on Equity (ROE) 86.0% -0.3%
4. Balance Sheet & Cash Flow LLY
Cash Generation (TTM) $11.7B $2.7M EBITDA
Cash Flow Margin 13.5% 1.1% EBITDA Mgn
Net Cash / Leverage $44.6B Net Debt (1.23x D/E) $1.01 Book/Sh · -0.3% ROE
Dividend Yield 0.48% None (0.00%)
5. Options & Positioning LLY
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 34.2% (23rd %ile) 2.4% (<1st %ile)
Put/Call OI Skew 0.95x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat LLY
OpEx & R&D Intensity 32.4% of Rev ($28.0B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Incretin Metabolic, Obesity & Cardiometabolic Biopharma Leader Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LLY (5) vs AVDL (5)
Institutional Metric LLY AVDL Criterion Row Edge
Market Capitalization
Scale
$1.20T $2.1B Larger Scale LLY
Trailing P/E Ratio
Valuation
44.9x 16.8x Lower Multiple AVDL
Forward P/E Ratio
Valuation
26.5x 28.8x Lower Multiple LLY
Revenue Growth (YoY)
Growth
+38.6% +54.9% Higher Growth AVDL
Operating Margin (TTM)
Profitability
51.2% 2.5% Higher Margin LLY
Net Profit Margin
Profitability
31.9% -0.1% Higher Margin LLY
Return on Equity (ROE)
Capital Efficiency
86.0% -0.3% Higher ROE LLY
52-Week Range Position
Momentum
80% ($851–$1,475) 89% ($6–$24) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.32β · 36% Vol 0.14β · 2% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
41.4 / 100 (SELL) 62.9 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$86.5B $249M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
83.6% 94.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.28x PEG · 14.4x EV/Rev 0.07x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$11.7B ($44.6B Net Debt (1.23x D/E)) $2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +6.74 pp
LLY: -6.09% · AVDL: +0.65%
3M Horizon LLY +3.04 pp
LLY: -3.28% · AVDL: -6.32%
6M Horizon LLY +3.04 pp
LLY: -3.28% · AVDL: -6.32%
1Y Horizon LLY +3.04 pp
LLY: -3.28% · AVDL: -6.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LLY vs AVDL. Trailing 12-month operating profitability (LLY 51.2% vs AVDL 2.5%) and valuation multiples (LLY 26.5x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

LLY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$86.5B
Gross Margin83.6%
Op. Margin51.2%
ROE / Fwd P/E86.0% · 26.5x
AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LLY CONSOLIDATION
97d in phase · OBV DISTRIBUTION
Current IV 34.2%
IV Percentile 23rd %ile
Put/Call OI Skew 0.95x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact LLY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $1,431.67 · IV 32.8%

LLY Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($143,167)

Compare $143,167 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 32.8% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $1,420 / $1,500 Bull Call Spread

Buy 1x $1,420C · Sell 1x $1,500C · 31d

Net Entry $3,575 Debit
T+5d @ +5% Move +$1,618 (+45%)
Max Risk / Buffer $3,575 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $1,340 / $1,220 Bull Put Spread

Sell 1x $1,340P · Buy 1x $1,220P · 31d

Net Entry $1,725 Credit
Max Credit / Yield +$1,725 (+16.8% RoM)
Max Risk / Buffer -7.6% Cushion ($10,275 Mgn)
5d Edge & Liquidity 76% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Dec 18 $1,340P / $1,460-$1,540C Seagull

Sell 1x $1,340P · Buy 1x $1,460/$1,540C · 31d

Net Entry $210 Debit
T+5d @ +5% Move +$3,040 (+13.9% RoM)
Max Risk / Buffer -6.4% Put Cushion ($21,901 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LLY Moat Profile High-Margin Pricing Power Moat
Incretin Metabolic, Obesity & Cardiometabolic Biopharma Leader
Anchors global GLP-1/GIP metabolic therapy demand backed by multi-billion-dollar sterile fill-finish and active ingredient manufacturing scale.
OpEx & R&D Reinvestment 32.4% of Rev ($28.0B)
90D Engineering Disclosures 0 Published
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LLY vs AVDL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Eli Lilly & Co. (LLY) on higher Unified Composite conviction (62.9/100 BUY vs. 41.4/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while LLY wins 5–1 across the 6-pillar growth and valuation breakdown. LLY trades at $1,347.11 (26.5x Forward P/E, 51.2% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. LLY 41.4/100 SELL) and 0.14β · 2% Vol risk profile, whereas LLY leads top-line expansion (+38.6% YoY revenue growth, 1.28x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

LLY leads the Growth & Scale pillar: LLY posts +38.6% YoY revenue growth and +16.3% YoY earnings growth on $86.5B TTM revenue (83.6% gross margin, 51.2% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, LLY generates $86.5B in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, LLY deploys 32.4% of Rev ($28.0B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.

AVDL screens cheaper on headline valuation multiples. LLY trades at 26.5x Forward P/E, 44.9x Trailing P/E, 1.28x PEG, and 14.4x EV/Revenue (13.5% FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LLY (86.0% ROE) versus AVDL (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, LLY carries 34.2% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.95x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 36% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.